Table of Contents
Table of Contents
Preface
Chapter 1 – Innovation in the Biopharmaceutical Pipeline (pp. 1-4)
Chapter 2 – The Diversity of Targeted Cancer Drugs Recently Approved by the FDA (pp. 5-14)
Chapter 3 – Chronological List of Targeted Cancer Drugs Approved by the FDA (pp. 15-22)
Chapter 4 – Targeted Therapies: Detailed Description (pp. 23-68)
Chapter 5 – Targeted Therapy for Chronic Lymphocytic Leukemia (CLL) (pp. 69-80)
Chapter 6 – Targeted Therapy for HER-2-Positive Breast Cancer (pp. 81-90)
Chapter 7 – Targeted Therapy for Metastatic Breast Cancer: Varia (pp. 91-96)
Chapter 8 – Targeted Therapy for Chronic Myelogenous Leukemia (CML) (pp. 97-108)
Chapter 9 – Targeted Therapy for Gastrointestinal Stromal Tumors (GIST) (pp. 109-116)
Chapter 10 – Targeted Therapy for Metastatic Colorectal Cancer (mCRC) (pp. 117-132)
Chapter 11 – Targeted Therapy for Metastatic Melanoma (McM) (pp. 133-146)
Chapter 12 – Targeted Therapy for Multiple Myeloma (MM) (pp. 147-156)
Chapter 13 – Targeted Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC) (pp. 157-168)
Chapter 14 – Targeted Therapy for Metastatic Renal Cell Carcinoma (mRCC) (pp. 169-180)
Chapter 15 – Targeted Therapy for Gastric Cancer (pp. 181-186)
Chapter 16 – Targeted Therapy for Non-Small Cell Lung Cancer (NSCLC) (pp. 187-202)
Chapter 17 – Targeted Therapy for Myelodysplastic Syndromes (MDS) (pp. 203-208)
Chapter 18 – Targeted Therapy for Mantle Cell Lymphoma (MCL) (pp. 209-214)
Chapter 19 – Abbreviations (pp. 215-218)
Chapter 20 – Generic Names – Trade Names: Equivalences (pp. 219-222)
Index
